【美股财报】Blueprint Medicines Corp 2024年度报告.pdf

Position on the Use of Artificial Intelligence in the Medicinal Product Lifecycle

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors

Medicine shortages: EFPIA proposal for action

Clearmind Medicine Inc 2025年年度报告和过渡报告

3D MEDICINES-B二零二二年年报

Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines

3D MEDICINES二零二三年年报

Disc Medicine Inc美股招股说明书(2025-01-23版)

Disc Medicine Inc美股招股说明书(2025-01-21版)

Annex 1 Socio-Economic Analysis Of the potential restriction of the perand polyfluoroalkyl substances (PFAS) used in the production, packaging and delivery of human medicinal products